Teva Lifts 2026 Sales Forecasts For AUSTEDO, AJOVY And UZEDY As Brand Growth Hits 33%

Three branded drugs grew 33% in local currency to about $1.1 billion, offsetting a 2% revenue dip from generic lenalidomide competition.

Share
Teva Lifts 2026 Sales Forecasts For AUSTEDO, AJOVY And UZEDY As Brand Growth Hits 33%

Teva Pharmaceutical Industries, the Israel-based maker of generic, biosimilar and brand-name medicines, raised its 2026 sales outlook for AUSTEDO, AJOVY and UZEDY after the three brands grew 33% in local currency to about $1.1 billion in the third quarter. Total revenue still slipped 2% to $4.4 billion, the company said Tuesday, as competition for its generic lenalidomide capsules, a copy of Revlimid, cut into U.S. generics sales.

Three brands, three higher ranges

Teva's quarterly results put AUSTEDO at $751 million, up 21% in local currency, AJOVY at $269 million, up 61%, and UZEDY at $85 million, up 96%.

The new full-year ranges:

  • AUSTEDO: $2.55 billion to $2.65 billion, from $2.45 billion to $2.60 billion.
  • AJOVY: $930 million to $960 million, from $850 million to $870 million.
  • UZEDY: $290 million to $310 million, from $270 million to $290 million.

CEO Richard Francis said the brands' performance and margin expansion give Teva "the confidence to raise our 2026 revenue outlook for all three brands." Company-wide, Teva now expects 2026 revenue of $16.7 billion to $17.0 billion, up from $16.5 billion to $16.85 billion.

Generics shrink, margins widen

Global generics revenue fell 16% in local currency. In the United States, generic sales dropped 39% to $718 million, mainly on lenalidomide capsules, and total U.S. segment revenue fell 11% to $1.87 billion.

The brand mix lifted adjusted gross margin to 58.7%, Teva's best quarter in ten years, excluding the $500 million duvakitug milestone payments booked in the fourth quarter of 2025. Adjusted operating income was $1.39 billion, a 31.7% margin versus 28.9% a year earlier.

On standard accounting, diluted earnings per share fell to $0.20 from $0.37, weighed by impairments, legal charges and a $224 million loss on retiring debt. Adjusted earnings per share rose 10% to $0.86.

Investment grade and a 2027 margin goal

Teva said Moody's and S&P upgraded it to investment grade during the quarter, following an earlier Fitch upgrade, and that it refinanced about $4.9 billion of debt. It is aiming for a 30% non-GAAP operating margin by 2027, plus about $700 million of net savings.

In Tuesday trading, Teva shares were at $42.57, up about 5% from the prior close of $40.70, giving the company a market value of $47.5 billion.

Launches and decisions ahead

The FDA approved WELTRUZA, a once-monthly injectable schizophrenia treatment, in October, and Teva expects it in U.S. pharmacies in the coming weeks. Teva targets peak sales of $1.5 billion to $2.0 billion for its long-acting schizophrenia injectables, UZEDY and WELTRUZA together.

The FDA accepted the ecopipam application for Tourette syndrome in children, with a decision expected in the first quarter of 2027.

Teva expects its biosimilars business to top $0.8 billion in 2026 revenue, hitting its original 2027 goal a year early.

Sources